EP Patent

EP3042910A2 — 2'-spiro-nucleosides for use in the therapy of hepatitis c

Assigned to Gilead Pharmasset LLC · Expires 2016-07-13 · 10y expired

What this patent protects

Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus, wherein B is selected from among B2 and B3 represented by the following structures:

USPTO Abstract

Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus, wherein B is selected from among B2 and B3 represented by the following structures:

Drugs covered by this patent

Patent Metadata

Patent number: EP3042910A2
Jurisdiction: EP
Classification: —
Expires: 2016-07-13
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.